Objectives: Characterize bone health surveillance patterns, bone mineral density (BMD) outcomes, and fracture risk after risk-reducing salpingo-oophorectomy (RRSO) in patients with BRCAmutations. Methods: An institutional review board-approved, retrospective review was performe of health surveillance among BRCA1/2mutation carriers after RRSO from the years 2000 to 2013. Women with occult carcinoma at RRSO were excluded from analysis. The primary outcome was the number of women who had a dual-energy X-ray absorptiometry (DEXA) scan after RRSO. Secondary outcomes included new diagnoses and time to diagnosis of osteopenia and osteoporosis. Incidence of fracture was also included. Information regarding hormone replacement therapy (HRT) was also recorded. Use of aromatase inhibitors, chemotherapy, and osteoporotic agents was not recorded. Results: A total of 192 BRCA mutation carriers underwent RRSO. Median age at the time of RRSO was 48 years. Approximately, 65% of the cohort was premenopausal at the time of surgery. Median follow-up was 6.5 years from date of surgery. DEXA scanning was performed in 97 (51%) women after RRSO, of which 48 patients had 1 or more test. Age, preoperative menopausal status, use of HRT, and length of follow-up were comparable between BRCA mutation carriers who had DEXA surveillance and those who did not. Seventy-six (78%) women had abnormal findings. Fifty-eight (60%) had osteopenia and 19 (20%) had osteoporosis. Median time to abnormal bone density was 24 months (range, 1-151). Fracture was seen in 10 patients (5%). In women younger than 50 years, the frequencies of osteopenia and osteoporosis were 66% and 11% compared with 50% and 31% in postmenopausal women (P = .08]. Thirty-five women (46%) who had DEXA surveillance used HRT. Women who used HRT had lower frequencies of osteopenia and osteoporosis than women who did not use HRT, 74% and 0.06% vs 83% and 22%, respectively (P = .09; OR 0.26, CI 0.06-1.22). Conclusions: Significant bone loss is common and develops rapidly in women after RRSO. Women with BRCA mutations who undergo RRSO are underscreened for BMD. HRT is associated with a lower risk of significant bone loss osteoporosis. Guidelines for screening in these individuals should be firmly established to reduce osteoporotic-related fracture risk in this population. Objectives: Many of the multigene panels used for oncology patients include low-to moderate-risk genes, for which there are no established consensus management guidelines. Because the clinical usefulness of identifying nonactionable mutations is unclear, we sought to determine if there are specific patient populations in which positive findings on multigene panels would be more likely to affect clinical management. Methods: We reviewed the medical records of all patients who underwent multigene panel testing at a single institution between May 2012 and December 2014. Results: Four hundred and fifty-four patients underwent multigene panel testing. The median patient age was 54 years (range, 25-91 years) and 435 (96%) were women. One hundred and thirty-three patients (29%) were Ashkenazi Jewish (AJ) and 93 (21%) were not Caucasian. Three hundred and fifty-four patients (78%) had a personal history of cancer. Forty-nine patients had ovarian cancer, 26 endometrial cancer, and 251 breast cancer. We identified 62 pathogenic mutations in 56 patients (12%) and 291 variants of uncertain significance in 196 patients (43%). Overall, 41 pathogenic mutations identified (66%) were actionable. Having a personal or family history of cancer or a specific diagnosis of ovarian, endometrial, or breast cancer did not affect the likelihood of identifying a clinically actionable mutation. Twenty pathogenic mutations were identified in 19 AJ patients, 18 of which were in genes other than BRCA1/2. Among those with pathogenic mutations, AJ patients were significantly more likely than non-AJ patients to harbor an actionable mutation (17 [85%] vs 24 [57%], P = .04). (See Fig. 1.) Conclusions: With the rapid acceptance of multigene panels, there is a pressing need to understand how this testing will affect patient management. We found that screening and prevention recommendations existed for 66% of the pathogenic mutations identified. In the AJ population, 85% of identified mutations were actionable, only 2 of which were in the BRCA1/2 genes. Our findings suggest that panel testing may be especially useful in the AJ population. Objectives: Hereditary endometrial carcinoma (EC) is associated with germline mutations in Lynch syndrome (LS) genes. The role of other cancer predisposition genes in EC is unclear. We aimed to Abstracts / Gynecologic Oncology 141 (2016) 2-208 
